 |
One Patient’s Experience: The Genesis Behind The New Microcyn HydroGel for DermatologyJim Schutz As you may have recently read, we received a clearance from the FDA for our new Microcyn Dermatology HydroGel product, our first dermatology product and a terrific new opportunity for the team at Oculus. We’ve been quizzed repeatedly the last several days for the “story” behind the new product and our push into dermatology. Bear with me for a peek behind the scenes.
Posted in
Dermatology by
Jim Schutz on
March 10th, 2010
|
 |
Keeping it in PerspectiveBy Hoji Alimi, Oculus Founder and CEO I just returned from three days in San Francisco where I presented at one of the largest investor healthcare conferences of the year. The economic sentiment this year, versus last, was upbeat and optimistic. As CEO of Oculus, I was elated to share with the investment community that Oculus has reached an inflection point in our growth, with seven new FDA clearances and product introductions targeted for the United States in 2010. The investors we met with this week along with the general market response has been favorable to our news.
Posted in
Global Outreach by
Hoji Alimi on
January 15th, 2010
|
 |
Microcyn® Technology vs. Antibiotics: A comparative view of Microcyn Technology products, liquids and gels, containing HOCl and topical and systemic products containing antibiotics.Dr. Eileen Thatcher The antimicrobial agent in Microcyn Technology is hypochlorous acid (HOCl), is found naturally produced in animals and humans for protection against infectious agents, including bacteria, viruses, yeasts and some fungi. This small molecule is nontoxic to host cells at the concentrations used in Microcyn Technology and does not cause the development of allergic reactions with repeated use.
Posted in
Antibiotics by
Eileen Thatcher on
January 5th, 2010
|
| |
Increasing Shareholder Value in 2010Hoji Alimi If you’ve read our recent press release, you know that the Oculus R&D and marketing teams have been quite busy crafting a regulatory and product strategy for 2010 that outlines an exciting list of milestones and provides a high level of transparency. In speaking with our shareholders, both large and small, there’s been a consistent question I’ve heard: “The financial strategy to reach breakeven is an important milestone. How will you increase revenue following the breakeven so that we can see (and calculate) a ramp in earnings per share?”
Posted in
New Microcyn Products by
Hoji Alimi on
December 14th, 2009
|
| |
 |
Silver-Based Wound Care ProductsRobert Northey Ph.D The antimicrobial properties of silver have been well known for centuries. In the ionic form Ag+, silver has good antimicrobial properties against a broad spectrum of gram-positive and gram-negative bacteria1,2. It is used in the treatment of burns and wounds for the reduction of bioburden. Silver, as soluble salts, chelates, or nano crystals, is applied topically in solutions, creams, or gels. It is also incorporated as a slow release agent into a wide variety of dressing.
Posted in
Silver-Based Wound Care Products by
Robert Northey, Ph.D on
November 24th, 2009
|
| |
A Sunday Update Over a Strong Cup of CoffeeJim Schutz We announced our earnings for the quarter ending September 30, 2009, on Thursday and we had a good quarter. We hit our numbers on both the revenue side ($1.7M – an increase of 37% in constant currency) and expense side (cash operating expenses were $2.7M). Borrowing a line from our tissue care sales team – our financials look “pink and healthy” and in light of these trying economic times, the patient has a bright future.
Posted in
Oculus Future by
Jim Schutz on
November 9th, 2009
|
| |
The Chemistry of Microcyn® TechnologyRobert Northey Ph.D The Microcyn™ Platform Technology generates stable, highly efficacious pH-neutral products based on the science of hypochlorous acid (HOCl). This chemical is a highly efficient, but under most conditions, an unstable antimicrobial agent that is generated by human cells as a defensive agent.
Posted in
Microcyn Technology by
Robert Northey, Ph.D on
October 28th, 2009
|